BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32762133)

  • 1. Metabolic behavior and prognostic role of pretreatment 18F-FDG PET/CT in gist.
    Albano D; Bosio G; Tomasini D; Bonù M; Giubbini R; Bertagna F
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e207-e215. PubMed ID: 32762133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of Pretreatment 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
    [No Abstract]   [Full Text] [Related]  

  • 7. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
    Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-[
    Albano D; Camoni L; Rodella C; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e277-e283. PubMed ID: 33386279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of
    Albano D; Camoni L; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 11. 2-[
    Albano D; Calabrò A; Dondi F; Bertagna F
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399491
    [No Abstract]   [Full Text] [Related]  

  • 12. Pretreatment quantitative
    Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
    Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients.
    Albano D; Mazzoletti A; Spallino M; Muzi C; Zilioli VR; Pagani C; Tucci A; Rossetti C; Giubbini R; Bertagna F
    Ann Hematol; 2020 Jun; 99(6):1321-1330. PubMed ID: 32333153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.
    Man S; Yan J; Li J; Cao Y; Hu J; Ma W; Liu J; Zhao Q
    Int J Med Sci; 2021; 18(8):1857-1865. PubMed ID: 33746603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.